Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
apatinib + albumin paclitaxel + carboplatin
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This combination therapy regimen consists of apatinib, albumin-bound paclitaxel (nab-paclitaxel), and carboplatin. Apatinib is a selective small-molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor 2 (VEGFR-2), functioning as an anti-angiogenic agent. Albumin paclitaxel is a microtubule inhibitor that promotes tubulin assembly and stabilizes microtubules, while carboplatin is a platinum-based chemotherapeutic agent that causes DNA cross-linking and inhibits DNA synthesis. This triplet combination is being evaluated in a Phase II clinical trial sponsored by The First Affiliated Hospital with Nanjing Medical University as a neoadjuvant therapy for patients with triple-negative breast cancer (TNBC). The study aims to assess the safety and efficacy of the regimen, specifically focusing on the pathologic complete response (pCR) rate. Apatinib is developed and manufactured by Hengrui Pharmaceutical.
- Other names
- Apatinib combined with Albumin Paclitaxel and Carboplatin
02
Targets
DNAVEGFR2 (Vascular endothelial growth factor receptor 2)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on apatinib + albumin paclitaxel + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on apatinib + albumin paclitaxel + carboplatin.